Zobrazeno 1 - 10
of 214
pro vyhledávání: ''
Autor:
Junji Uchino, Akira Nakao, Osamu Hiranuma, Yusuke Chihara, Masahiro Iwasaku, Takashi Kijima, Chieko Takumi, Yoshiko Kaneko, Takahiro Yamada, Masafumi Takeshita, Makoto Hibino, Yoshie Morimoto, Koichi Takayama, Kenji Morimoto, Takayuki Takeda, Tadaaki Yamada, Yasuhiro Goto, Hiroyuki Yamaguchi, Takashi Yokoi
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 161
Combination therapy of immune checkpoint inhibitors and chemotherapy is considered to be one of the standard treatment options for patients with advanced non-small-cell lung cancer (NSCLC). However, the clinical significance of immune checkpoint inhi
Autor:
Michael Cabanero, Xuyang Song, Rosalyn A. Juergens, Penelope A. Bradbury, Phillip A. Dennis, John Hilton, P. Brown-Walker, Desiree Hao, John R. Goffin, Sebastien J. Hotte, Anna Tomiak, Gwyn Bebb, Scott A. Laurie, Andrew Robinson, Martin Smoragiewicz, Christian K. Kollmannsberger, I. Gauthier, Moustapha Tehfe, Xiaoqun Sun, Peter M. Ellis, Dongsheng Tu, Paul Wheatley-Price, Mihaela Mates, Janessa Laskin, Glenwood D. Goss, Lesley Seymour, Ming-Sound Tsao
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 143
This multicenter phase Ib study aimed to establish a recommended phase II dose for durvalumab (Du) ± tremelimumab (Tr) in combination with standard platinum-doublet chemotherapy. Eligible patients were enrolled into one of six dose levels (DL) of Du
Autor:
Yin Shi, Youwen Zhu, Dong Ding, Shan Zeng, David P. Carbone, Longjiang She, Linli Yao, Liangfang Shen, Xuefeng Xia, Mengting Liao, Huabin Hu, Jin Huang
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 138
Objective The purpose of this study was to estimate the cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advance or metastatic non-small cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1
Autor:
Ye Li, Lin Wu, Qian Chu, Zheng-Bo Han, Gen Lin, Wen-Zhao Zhong, Yi-Long Wu, Fan Yang, Bo Zhu, Hong-Mei Zhang, Jinliang Wang, Jie Hu, Meng-Xia Li, Jia-Tao Zhang, Li-Xu Yan, Huijuan Wang, Zhengfei Zhu, Xiao-Rong Dong, C. Xu, Zhengbo Song, Jie Lin, Zong-Yang Yu
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 139
Objectives The 2015 World Health Organization classification defines pulmonary large-cell neuroendocrine carcinoma (LCNEC) as a high-grade neuroendocrine carcinoma. However, the clinical characteristics and prognostic factors of pure LCNEC and combin
Autor:
Chen Chen, Xuanye Zhang, Tao Chen, Haifeng Li, Li na He, Yuhong Wang, Li Zhang, Sha Fu, Yixin Zhou, Zuan Lin, Shaodong Hong
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 137
Pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare subtype of primary lung cancer. Due to the lack of prospective studies, the optimal first-line chemotherapy regimens and survival outcomes remain unclear.This real-world, retrospective study
Autor:
J. Crawford, Chen Shen, Melisa L. Wong, Thomas E. Stinchcombe, Xiaofei Wang, Herbert Pang, James Chung-Man Ho, Yingzhou Liu, Xiaowen Cao, Apar Kishor Ganti
Publikováno v:
Lung Cancer
Objectives Neutropenia is associated with the risk of life-threatening infections, chemotherapy dose reductions and delays that may compromise outcomes. This analysis was conducted to develop a prediction model for chemotherapy-induced severe neutrop
Autor:
Riichiroh Maruyama, Kaoru Kubota, Noriyuki Masuda, Naoki Shimada, Masahiko Shibuya, Hideo Kunitoh, Takashi Seto, Masahiro Tsuboi, Tatsuo Ohhira, Koshiro Watanabe, Hiroaki Okamoto
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 141
Objective Adjuvant chemotherapy is standard of care for patients with completely resected stage IB, II and IIIA NSCLC. However, optimum chemotherapy regimen has not been determined. TORG0503 was undertaken to select a preferred platinum-based 3rd gen
Autor:
Kenya Kanazawa, Takashi Umeda, Ryuichi Togawa, Julia Morimoto, Yuki Sato, Hiroyuki Minemura, Takaya Kawamata, Tatsuhiko Koizumi, Takefumi Nikaido, Natsumi Watanabe, Yoko Shibata, Hikaru Tomita, Atsuro Fukuhara, Mami Rikimaru, Kiyoshi Mori, Kenichiro Hirai, Yoshinori Tanino, Mikako Saito, Junpei Saito, Risa Kanai, Yasuhito Suzuki, Manabu Uematsu, Suguru Sato
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 136
Objectives Thrombotic thrombocytopenic purpura (TTP) is a rare form of thrombotic microangiopathy. In recent years, an extensive variety of drugs, including certain cytotoxic agents, have been reported to be associated with TTP. Additionally, several
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 133
Objective To explore the efficacy and safety of icotinib with chemotherapy as first-line therapy for advanced lung adenocarcinoma in patients with sensitive epidermal growth factor receptor (EGFR) mutations. Methods This prospective, randomized, cont
Autor:
John R. Goffin, Samantha Gray, Paul Wheatley-Price, Nevin Murray, Charles Butts, Normand Blais, Penelope A. Bradbury, Jenny Ko, Garth Nicholas, P. Brown-Walker, Scott A. Laurie, Marie Florescu, Jeffrey Rothenstein, Pardeep Kaurah, Cynthia Card, M. Neil Reaume, Dongsheng Tu, Leah M. Prentice, Natasha B. Leighl, Lesley Seymour, Hongbo Lui, Barbara Melosky, Anthony Reiman, Naveen S. Basappa, Glenwood D. Goss
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 133
Introduction Activation of the RAS/RAF/MEK/ERK pathway may confer resistance to chemotherapy in non-small cell lung cancer (NSCLC). Selumetinib (AZD6244, ARRY142886), a MEK1/2 inhibitor combined with chemotherapy in patients with NSCLC was evaluated